Natural killer cells and malignant haemopathies: A model for the interaction of cancer with innate immunity

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 1-13

  Sanchez, C J ^a,b,c   Le Treut, T ^a,c   Boehrer, A ^a   Knoblauch, B ^a   Imbert, J ^c   Olive, D ^b,d   Costello, R T ^a,b,c,e  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Aix Marseille university   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Antitumour response; Immune modulation; Innate immunity; Natural killer cells

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BORTEZOMIB; BUTYRIC ACID; CD16 ANTIGEN; DASATINIB; HISTAMINE; HISTONE DEACETYLASE INHIBITOR; HLA ANTIGEN; IMATINIB; IMMUNOMODULATING AGENT; LENALIDOMIDE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NILOTINIB; PANOBINOSTAT; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR ESCAPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; TUMOR ESCAPE;

EID: 79953765645     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0898-x     Document Type: Review

References (102)

1. Caligiuri MA (2008) Human natural killer cells. Blood 112:461-469
2. Vivier E (2006) What is natural in natural killer cells? Immunol Lett 107:1-7
3. Bottino C, Moretta L, Pende D et al (2004) Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol Immunol 41:569-575 (Pubitemid 38824614)
4. Garrido F, Cabrera T, Lopez-Nevot MA et al (1995) HLA class I antigens in human tumors. Adv Cancer Res 67:155-195
5. Biassoni R, Cantoni C, Pende D et al (2001) Human natural killer cell receptors and co-receptors. Immunol Rev 181:203-214 (Pubitemid 32703408)
6. Moretta A, Biassoni R, Bottino C et al (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 21:228-234 (Pubitemid 30259028)
7. Watzl C (2003) The NKG2D receptor and its ligands - recognition beyond the "missing self"? Microbes Infect 5:31-37
8. Arnon TI, Achdout H, Levi O et al (2005) Inhibition of the NKp30 activating receptor by pp65 of human cytomegalo-virus. Nat Immunol 6:515-523 (Pubitemid 41716765)
9. Arnon TI, Lev M, Katz G et al (2001) Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 31:2680-2689 (Pubitemid 32898735)
10. Mandelboim O, Lieberman N, Lev M et al (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409:1055-1060 (Pubitemid 32204059)
11. Biassoni R, Cantoni C, Marras D et al (2003) Human natural killer cell receptors: insights into their molecular function and structure. J Cell Mol Med 7:376-387 (Pubitemid 44151688)
12. Clark P, Normansell DE, Innes DJ et al (1986) Lymphocyte subsets in normal bone marrow. Blood 67:1600-1606 (Pubitemid 16075963)
13. Rego EM, Garcia AB, Viana SR et al (1998) Age-related changes of lymphocyte subsets in normal bone marrow biopsies. Cytometry 34:22-29
14. Freud AG, Becknell B, Roychowdhury S et al (2005) A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22:295-304 (Pubitemid 40387472)
15. Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100 (Pubitemid 34229476)
16. Kiladjian JJ, Bourgeois E, Lobe I et al (2006) Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 20:463-470 (Pubitemid 43291745)
17. Kerndrup G, Meyer K, Ellegaard J et al (1984) Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leuk Res 8:239-247 (Pubitemid 14149201)
18. Yokose N, Ogata K, Ito T et al (1994) Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. Leuk Res 18:777-782 (Pubitemid 24302105)
19. Epling-Burnette PK, Bai F, Painter JS et al (2007) Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 109:4816-4824 (Pubitemid 46827777)
20. Verhoef GE, De Shouwer P, Ceuppens JL et al (1992) Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6:1268-1272 (Pubitemid 23054024)
21. James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148 (Pubitemid 40663494)
22. Froom P, Aghai E, Kinarty A et al (1989) Decreased natural killer (NK) activity in patients with myeloproliferative disorders. Cancer 64:1038-1040 (Pubitemid 19208855)
23. Chang WC, Fujimiya Y, Casteel N et al (1989) Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells. Int J Cancer 43:591-597 (Pubitemid 19110092)
24. Pierson BA, Miller JS (1996) CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 88:2279-2287 (Pubitemid 26307932)
25. Chiorean EG, Dylla SJ, Olsen K et al (2003) BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin- like receptors (KIRs). Blood 101:3527-3533 (Pubitemid 36857938)
26. Boissel N, Rea D, Tieng V et al (2006) BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 176:5108-5116
27. Gersuk GM, Carmel R, Pattamakom S et al (1993) Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity. Nat Immun 12:136-151
28. Costello RT, Sivori S, Marcenaro E et al (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99:3661-3667 (Pubitemid 34534536)
29. Sivori S, Pende D, Bottino C et al (1999) NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 29:1656-1666 (Pubitemid 29224471)
30. Moretta A, Bottino C, Vitale M et al (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197-223 (Pubitemid 32368034)
31. Pende D, Cantoni C, Rivera P et al (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31:1076-1086
32. Fauriat C, Just-Landi S, Mallet F et al (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCR-dull phenotype induction. Blood 109:323-330 (Pubitemid 46053073)
33. Salih HR, Antropius H, Gieseke F et al (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389-1396 (Pubitemid 36988048)
34. Pant S, Copelan EA (2007) Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 13:877-885 (Pubitemid 47055392)
35. King MA, Radicchi-Mastroianni MA (1996) Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry 26:121-124 (Pubitemid 26238184)
36. Matsuzaki H, Kagimoto T, Oda T et al (1985) Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma. Jpn J Clin Oncol 15:611-617
37. Maki G, Hayes GM, Naji A et al (2008) NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 22:998-1006 (Pubitemid 351689882)
38. Fauriat C, Mallet F, Olive D, Costello RT (2006) Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 20:732-733
39. Carbone E, Neri P, Mesuraca M et al (2005) HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105:251-258
40. Jarahian M, Watzl C, Issa Y et al (2007) Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int J Cancer 120:2625-2634 (Pubitemid 46651284)
41. Groh V, Wu J, Yee C et al (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738 (Pubitemid 35177960)
42. Jinushi M, Vanneman M, Munshi NC et al (2008) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 105:1285-1290 (Pubitemid 351397045)
43. Saverino D, Fabbi M, Ghiotto F et al (2000) The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J Immunol 165:3742-3755 (Pubitemid 32057280)
44. Rouas-Freiss N, Moreau P, Ferrone S et al (2005) HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 65:10139-10144
45. Palmer S, Hanson CA, Zent CS et al (2008) Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 141:607-614 (Pubitemid 351667615)
46. Katrinakis G, Kyriakou D, Papadaki H et al (1996) Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol 96:16-23 (Pubitemid 26187968)
47. Verheyden S, Ferrone S, Mulder A et al (2009) Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells. Cancer Immunol Immunother 58:855-865
48. Poggi A, Venturino C, Catellani S et al (2004) Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 64:9172-9179 (Pubitemid 39665533)
49. Romanski A, Bug G, Becker S et al (2005) Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 33:344-352 (Pubitemid 40261316)
50. Sorskaar D, Lie SO, Forre O (1985) Natural killer cell activity of peripheral blood and bone marrow mononuclear cells from patients with childhood acute lymphoblastic leukemia. Acta Paediatr Scand 74:433-437 (Pubitemid 15034486)
51. Reid GS, Bharya S, Klingemann HG et al (2002) Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line. Clin Exp Immunol 129:265-271
52. Pende D, Castriconi R, Romagnani P et al (2006) Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107:2030-2036
53. Nguyen S, Dhedin N, Vernant JP et al (2005) NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 105:4135-4142 (Pubitemid 40656166)
54. Schulze A, Schirutschke H, Oelschlagel U et al (2008) Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol 36:378-389
55. Buser A, Stern M, Arber C et al (2008) Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab? Bone Marrow Transplant 42:483-487
56. Vitale C, Chiossone L, Morreale G et al (2004) Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur J Immunol 34:455-460 (Pubitemid 39255956)
57. Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376-383 (Pubitemid 40967217)
58. Muller T, Uherek C, Maki G et al (2008) Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57:411-423 (Pubitemid 350295385)
59. Pegram HJ, Jackson JT, Smyth MJ et al (2008) Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol 181:3449-3455
60. de Romeuf C, Dutertre CA, Le Garff-Tavernier M et al (2008) Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 140:635-643 (Pubitemid 351300917)
61. Sheridan C (2006) First-in-class cancer therapeutic to stimulate natural killer cells. Nat Biotechnol 24:597
62. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595-601
63. Xiang J, Chen Z, Huang H et al (2001) Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells. Leuk Res 25:909-915 (Pubitemid 32776582)
64. Chan CJ, Andrews DM, Smyth MJ (2008) Can NK cells be a therapeutic target in human cancer? Eur J Immunol 38:2964-2968
65. Hallett WH, Ames E, Alvarez M et al (2008) Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transplant 14:1088-1099
66. Wendt K, Wilk E, Buyny S et al (2007) Interleukin-21 differentially affects human natural killer cell subsets. Immunology 122:486-495 (Pubitemid 350075955)
67. Kobayashi H, Dubois S, Sato N et al (2005) Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105:721-727 (Pubitemid 40070758)
68. Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest 117:1184-1194
69. Gregoire C, Chasson L, Luci C et al (2007) The trafficking of natural killer cells. Immunol Rev 220:169-182 (Pubitemid 350045566)
70. Catusse J, Wollner S, Leick M et al (2010) Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol [Epub ahead of print]
71. Kittang AO, Hatfield K, Sand K et al (2010) The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol [Epub ahead of print]
72. Maghazachi AA (2010) Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol [Epub ahead of print]
73. Brune M, Castaigne S, Catalano J et al (2006) Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 108:88-96 (Pubitemid 43996626)
74. Romero AI, Thoren FB, Aurelius J et al (2009) Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 70:194-205
75. Brandau S, Riemensberger J, Jacobsen M et al (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92:697-702 (Pubitemid 32385713)
76. Borg C, Terme M, Taieb J et al (2004) Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114:379-388 (Pubitemid 39071610)
77. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G et al (2008) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140:36-45 (Pubitemid 350233246)
78. Lundqvist A, Abrams SI, Schrump DS et al (2006) Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 66:7317-7325 (Pubitemid 44197714)
79. Shi J, Tricot GJ, Garg TK et al (2008) Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111:1309-1317 (Pubitemid 351213417)
80. Soriani A, Zingoni A, Cerboni C et al (2009) ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113:3503-3511
81. Butler JE, Moore MB, Presnell SR et al (2009) Proteasome regulation of ULBP1 transcription. J Immunol 182:6600-6609
82. Wang X, Ottosson A, Ji C et al (2009) Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 94:470-478
83. Rohner A, Langenkamp U, Siegler U et al (2007) Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res 31:1393-1402 (Pubitemid 47212430)
84. Tang KF, He CX, Zeng GL et al (2008) Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine. Biochem Biophys Res Commun 370:578-583
85. Santourlidis S, Trompeter HI, Weinhold S et al (2002) Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 169:4253-4261 (Pubitemid 35178197)
86. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148-1159
87. Kato N, Tanaka J, Sugita J et al (2007) Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 21:2103-2108
88. Zhang C, Wang Y, Zhou Z et al (2009) Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58:1275-1285
89. Diermayr S, Himmelreich H, Durovic B et al (2008) NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111:1428-1436 (Pubitemid 351213430)
90. Ogbomo H, Michaelis M, Kreuter J et al (2007) Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 581:1317-1322 (Pubitemid 46452605)
91. Riemersma SA, Jordanova ES, Schop RF et al (2000) Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96:3569-3577
92. Murray PG, Constandinou CM, Crocker J et al (1998) Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 92:2477-2483
93. Nouri AM, Smith S, Oliver TR et al (1998) Comparative expression of major histocompatibility complex (MHC) antigens on CD5+ and CD5- B cells in patients with chronic lymphocytic leukaemia (CLL). Eur J Cancer 34:1618-1622 (Pubitemid 28446348)
94. Brouwer RE, van der Heiden P, Schreuder GM et al (2002) Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol 63:200-210 (Pubitemid 34246053)
95. Masuda K, Hiraki A, Fujii N et al (2007) Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci 98:102-108 (Pubitemid 44803927)
96. Wetzler M, Baer MR, Stewart SJ et al (2001) HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 15:128-133 (Pubitemid 32124077)
97. Demanet C, Mulder A, Deneys V et al (2004) Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 103:3122-3130
98. Vollmer M, Li L, Schmitt A et al (2003) Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol 120:1000-1008 (Pubitemid 36411559)
99. Lemoli RM, Salvestrini V, Bianchi E et al (2009) Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a. Blood 114:5191-5200
100. Verheyden S, Bernier M, Demanet C (2004) Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 18:2002-2007 (Pubitemid 40028427)
101. Sconocchia G, Lau M, Provenzano M et al (2005) The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 106:3666-3672 (Pubitemid 41609209)
102. Robertson MJ (2002) Role of chemokines in the biology of natural killer cells. J Leukoc Biol 71:173-183